View ValuationVictrex 향후 성장Future 기준 점검 3/6Victrex (는) 각각 연간 96% 및 4.5% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 75.7% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 14.3% 로 예상됩니다.핵심 정보96.0%이익 성장률75.69%EPS 성장률Chemicals 이익 성장17.3%매출 성장률4.5%향후 자기자본이익률14.33%애널리스트 커버리지Good마지막 업데이트15 May 2026최근 향후 성장 업데이트공시 • Feb 09Victrex plc Provides Earnings Guidance for the First Half and Full Year of Fiscal Year 2024Victrex plc provided earnings guidance for the first half and full year of fiscal year 2024. First half revenue is expected to be lower than the prior year period.The Group previously communicated that progress in revenue for fiscal year 2024.모든 업데이트 보기Recent updates공시 • May 20Victrex plc Announces Stepping Down of David Thomas as Non-Executive Director, Effective May 18, 2026Victrex PLC announces that David Thomas has informed the Board that he has stepped down as a Non-executive director of the Company with immediate effect on May 18, 2026, due to ill health. David Thomas was appointed as Non-executive director in 2018.공시 • May 12Victrex plc Announces Interim Dividend for the Six Months Ended 31 March 2026, Payable on 26 June 2026Victrex plc announced interim dividend for the six months ended 31 March 2026 of 13.42 pence per share will be paid on 26 June 2026 to shareholders on the register at the close of business on 29 May 2026. This dividend will be recognised in the period in which it is approved.공시 • Feb 11Victrex plc Announces Changes to Its Board and CommitteeSpirax Group plc announced the appointment of Maria Antoniou, Non-Executive Director and Chair of the Remuneration Committee, has been appointed as a Non-Executive Director of Victrex plc with effect from 1 September 2026. Victrex plc also announced the appointment of Peter Kiernan as non-executive director and David Thomas, non-executive director and Chair of the Audit Committee, will retire from the Board on 1 July 2026, and Peter will succeed David as Chair of the Audit Committee from that date. Peter Kiernan has significant experience in executive and non-executive roles. He had a 30 year career in investment banking with a focus on M&A and general corporate finance advice, including senior roles at S.G. Warburg/UBS, Goldman Sachs, Lazard and Hawkpoint Partners/Canaccord Genuity. He started his career at Peat, Marwick, Mitchell where he qualified as a Chartered Accountant. He holds an MA in Natural Sciences (Chemistry) from Cambridge University. Peter has held several advisory and non-executive positions. He currently holds senior advisory roles at Egon Zehnder and OMERS Private Equity (Europe). Prior non-executive roles include Tungsten Corporation, a public company where he was Audit Committee Chair and Senior Independent Director, Lifeways Group, a private equity owned business where he was Audit Committee Chair and Chair, and Business LDN where he was Chair of the Finance Committee. MariaAntoniou has extensive experience in both executive and non-executive roles within UK plc Boards. She is currently Chief Human Resources Officer at Morgan Advanced Materials plc and a non-executive director at FTSE 100 listed Spirax Group plc. Until last year she was a non-executive director of NATS (the National Air Traffic Service). Maria has a strong background in international industrial businesses, having worked in significant roles at Ford, Jaguar Land Rover and E.ON. Her experience spans across various sectors, including automotive, energy, and advanced materials, which gives her a comprehensive understanding of the challenges and opportunities within industries aligned to Victrex's end-markets.공시 • Feb 06Jakob Sigurdsson Steps Down as an Executive Director of Victrex Plc, Effective from February 6, 2026Coats Group PLC announces that it has been notified that Jakob Sigurdsson, a Non-Executive Director of the Company, has on February 6, 2026, stepped down as an Executive Director of Victrex plc.공시 • Oct 22Victrex plc, Annual General Meeting, Feb 06, 2026Victrex plc, Annual General Meeting, Feb 06, 2026.공시 • Oct 21+ 1 more updateVictrex plc Announces CEO ChangesVictrex plc announced that James Routh will join the Company as Chief Executive Officer with effect from 1 January 2026, succeeding Jakob Sigurdsson. He will join the Board as an Executive Director from the same date. Jakob Sigurdsson will continue to serve on the Victrex Board as Chief Executive until James joins, to support an orderly transition, and then as an Executive Director. Jakob will step down from the Board at the conclusion of the Company's Annual General Meeting on 6 February 2026.공시 • Jul 08+ 2 more updatesVictrex plc to Report Fiscal Year 2025 Results on Dec 02, 2025Victrex plc announced that they will report fiscal year 2025 results on Dec 02, 2025공시 • Dec 06Victrex plc, Annual General Meeting, Feb 07, 2025Victrex plc, Annual General Meeting, Feb 07, 2025.공시 • Dec 03Victrex plc Proposes Final Dividend for the Fiscal Year 2025, Payable on 21 February 2025Victrex plc at its AGM to be held on 7 February 2025, proposed final dividend at 46.14 pence per share (fiscal year 2024: 46.14 pence per share), with an Ex-dividend date: 23 January 2025, Record date: 24 January 2025 and Payment of final dividend: 21 February 2025.공시 • Sep 18Victrex plc Announces in Partnership with Maxx Orthopedics Inc, FDA Grants IDE Approval for Freedom Total Knee System with Invibio PEEK-OPTIMA Femoral Component as Staged StudyVictrex plc announced that, in partnership with Maxx Orthopedics Inc, the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval for Freedom Total Knee System with Invibio PEEK-OPTIMA Femoral Component, as a staged study. The study, projected to be 120 patients at clinical sites in the US, will compare using the PEEK-OPTIMA Femoral Knee Component to a controlled registry of the same system using traditional metal femoral components. The US study will build on the existing clinical trial for PEEK Knee at sites in Belgium, India and Italy, which has been progressing strongly since the first implant in 2021, with no clinical intervention. A regulatory submission in India is also expected imminently, supporting the potential for a commercial PEEK Knee in the market in 2025.공시 • Sep 06Victrex plc to Report Fiscal Year 2024 Results on Dec 03, 2024Victrex plc announced that they will report fiscal year 2024 results on Dec 03, 2024공시 • May 15Victrex plc Announces Interim Dividend , Payable on June 28, 2024Victrex plc announced that an interim dividend of 13.42 pence per share (First half 2023: 13.42 pence) will be paid on 28 June 2024 to shareholders on the register at the close of business on 31 May 2024. This dividend will be recognised in the period in which it is approved.공시 • Mar 15Victrex plc Appoints Urmi Prasad Richardson as Non-Executive Director, Effective from May 1, 2024Victrex plc announced that Urmi Prasad Richardson has been appointed as a non-executive director of the Board, effective from May 1, 2024. Urmi has a wealth of global experience in executive and non-executive roles over a 25 year period. She has a particular focus on science, medical and innovation based businesses. Urmi is currently President EMEA of Thermo Fisher Scientific, a world leader in serving science, with products which help accelerate life science research and improve patient health. Her executive career includes roles at The Linde Group, where she was Global Head of Healthcare, at Novartis and Foundation Medicine (a Roche company). She started her career with G.D. Searle (a Pfizer company) and has worked throughout Europe and the US. Urmi has extensive experience in strategy, business development and product commercialisation in Europe, Asia and North America. Urmi holds a number of advisory Board roles at unlisted organizations in the sectors of longevity, blockchain, and targeted therapy in oncology. Her previous non-executive roles include Linde Healthcare.공시 • Feb 27Victrex plc to Report First Half, 2024 Results on May 13, 2024Victrex plc announced that they will report first half, 2024 results on May 13, 2024공시 • Feb 09Victrex plc Provides Earnings Guidance for the First Half and Full Year of Fiscal Year 2024Victrex plc provided earnings guidance for the first half and full year of fiscal year 2024. First half revenue is expected to be lower than the prior year period.The Group previously communicated that progress in revenue for fiscal year 2024.공시 • Dec 05+ 1 more updateVictrex plc, Annual General Meeting, Feb 09, 2024Victrex plc, Annual General Meeting, Feb 09, 2024.공시 • Oct 14Victrex Announces New Product Grade Launch, Victrex Pharmaceutical Contact (PC)101 (VICTREX PC101), Developed Exclusively for the Drug Delivery Device MarketVictrex plc have launched a new product grade developed exclusively for Drug Delivery and Pharmaceutical Contact applications. VICTREX PC101™ meets the highest levels of Industry biocompatibility certification for USP Class VI and also meets industry standards such as USP 661 for use in non-implantable pharmaceutical contact applications. This material is available in granules and film and adds value to pharmaceutical production companies and drug delivery device manufacturers by providing access to assured materials for equipment or devices. This has the potential to save them cost, time and reduce risk, ultimately streamlining the commercialisation of their own products. VICTREX PC101™ is a PEEK-based material ideally suited to non-implantable Pharmaceutical contact and drug delivery applications for less than 24-hour tissue contact duration, whether they are production line equipment or primary packaging and end delivery devices. Victrex also offers unparalleled expertise, experience and support to customers, having been the first to commercialise the use of PEEK over 40 years ago. PEEK materials have properties meeting high levels of physical and chemical performance, ideal for applications requiring sterilisation, retention of dimensional stability, or chemical, electrical and temperature resistance. PEEK also meets high levels of mechanical performance, perfectly suited for high strength and miniature parts, wear, abrasion and fatigue exposure. It is also versatile for thermoplastic processing through moulding processes, milling or additive manufacturing. Victrex offer a unique perspective on this market as their medical business, Invibio, has over 20 years of proven clinical history in implantable medical PEEK devices. This insight and experience have enabled them to become a key player in the drug delivery device space over recent years. They are well placed to collaborate with OEMs, engineers and pharma manufacturing companies to support them from design, regulatory approval, manufacture and beyond.공시 • Jul 07Victrex plc to Report Q4, 2023 Results on Dec 04, 2023Victrex plc announced that they will report Q4, 2023 results on Dec 04, 2023공시 • May 10+ 1 more updateVictrex plc to Report Q2, 2023 Results on May 09, 2023Victrex plc announced that they will report Q2, 2023 results on May 09, 2023공시 • Dec 06Victrex plc, Annual General Meeting, Feb 10, 2023Victrex plc, Annual General Meeting, Feb 10, 2023.이익 및 매출 성장 예측OTCPK:VTXP.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (GBP Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수9/30/2028329454874119/30/2027313414468129/30/20262975446273/31/2026294-204969N/A12/31/202529344970N/A9/30/2025293284971N/A6/30/2025295295778N/A3/31/2025298306585N/A12/31/2024294235884N/A9/30/2024291175184N/A6/30/2024288243267N/A3/31/2024284311351N/A12/31/202329646846N/A9/30/202330762342N/A6/30/2023325671656N/A3/31/2023343722970N/A12/31/2022342743275N/A9/30/2022341763580N/A6/30/2022328734290N/A3/31/20223167049101N/A12/31/20213117267114N/A9/30/20213067385127N/A6/30/20212866473108N/A3/31/2021265546090N/A12/31/2020266545279N/A9/30/2020266544569N/A6/30/2020283725479N/A3/31/2020300896389N/A12/31/201929791N/A85N/A9/30/201929492N/A80N/A6/30/201930096N/A85N/A3/31/201930599N/A91N/A12/31/2018316105N/A110N/A9/30/2018326111N/A129N/A6/30/2018326113N/A127N/A3/31/2018326115N/A125N/A12/31/2017308107N/A121N/A9/30/2017290100N/A118N/A6/30/201727892N/A114N/A3/31/201726684N/A111N/A12/31/201625983N/A97N/A9/30/201625283N/A83N/A6/30/201625181N/A78N/A3/31/201625080N/A72N/A12/31/201525782N/A80N/A9/30/201526484N/A88N/A6/30/201526384N/A96N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: VTXP.F 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3.5%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: VTXP.F (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: VTXP.F 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: VTXP.F 의 수익(연간 4.5%)이 US 시장(연간 11.7%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: VTXP.F 의 수익(연간 4.5%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: VTXP.F의 자본 수익률은 3년 후 14.3%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YMaterials 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 04:03종가2026/05/19 00:00수익2026/03/31연간 수익2025/09/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Victrex plc는 31명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Gunther ZechmannBarclaysKatie RichardsBarclaysJames StewartBarclays28명의 분석가 더 보기
공시 • Feb 09Victrex plc Provides Earnings Guidance for the First Half and Full Year of Fiscal Year 2024Victrex plc provided earnings guidance for the first half and full year of fiscal year 2024. First half revenue is expected to be lower than the prior year period.The Group previously communicated that progress in revenue for fiscal year 2024.
공시 • May 20Victrex plc Announces Stepping Down of David Thomas as Non-Executive Director, Effective May 18, 2026Victrex PLC announces that David Thomas has informed the Board that he has stepped down as a Non-executive director of the Company with immediate effect on May 18, 2026, due to ill health. David Thomas was appointed as Non-executive director in 2018.
공시 • May 12Victrex plc Announces Interim Dividend for the Six Months Ended 31 March 2026, Payable on 26 June 2026Victrex plc announced interim dividend for the six months ended 31 March 2026 of 13.42 pence per share will be paid on 26 June 2026 to shareholders on the register at the close of business on 29 May 2026. This dividend will be recognised in the period in which it is approved.
공시 • Feb 11Victrex plc Announces Changes to Its Board and CommitteeSpirax Group plc announced the appointment of Maria Antoniou, Non-Executive Director and Chair of the Remuneration Committee, has been appointed as a Non-Executive Director of Victrex plc with effect from 1 September 2026. Victrex plc also announced the appointment of Peter Kiernan as non-executive director and David Thomas, non-executive director and Chair of the Audit Committee, will retire from the Board on 1 July 2026, and Peter will succeed David as Chair of the Audit Committee from that date. Peter Kiernan has significant experience in executive and non-executive roles. He had a 30 year career in investment banking with a focus on M&A and general corporate finance advice, including senior roles at S.G. Warburg/UBS, Goldman Sachs, Lazard and Hawkpoint Partners/Canaccord Genuity. He started his career at Peat, Marwick, Mitchell where he qualified as a Chartered Accountant. He holds an MA in Natural Sciences (Chemistry) from Cambridge University. Peter has held several advisory and non-executive positions. He currently holds senior advisory roles at Egon Zehnder and OMERS Private Equity (Europe). Prior non-executive roles include Tungsten Corporation, a public company where he was Audit Committee Chair and Senior Independent Director, Lifeways Group, a private equity owned business where he was Audit Committee Chair and Chair, and Business LDN where he was Chair of the Finance Committee. MariaAntoniou has extensive experience in both executive and non-executive roles within UK plc Boards. She is currently Chief Human Resources Officer at Morgan Advanced Materials plc and a non-executive director at FTSE 100 listed Spirax Group plc. Until last year she was a non-executive director of NATS (the National Air Traffic Service). Maria has a strong background in international industrial businesses, having worked in significant roles at Ford, Jaguar Land Rover and E.ON. Her experience spans across various sectors, including automotive, energy, and advanced materials, which gives her a comprehensive understanding of the challenges and opportunities within industries aligned to Victrex's end-markets.
공시 • Feb 06Jakob Sigurdsson Steps Down as an Executive Director of Victrex Plc, Effective from February 6, 2026Coats Group PLC announces that it has been notified that Jakob Sigurdsson, a Non-Executive Director of the Company, has on February 6, 2026, stepped down as an Executive Director of Victrex plc.
공시 • Oct 22Victrex plc, Annual General Meeting, Feb 06, 2026Victrex plc, Annual General Meeting, Feb 06, 2026.
공시 • Oct 21+ 1 more updateVictrex plc Announces CEO ChangesVictrex plc announced that James Routh will join the Company as Chief Executive Officer with effect from 1 January 2026, succeeding Jakob Sigurdsson. He will join the Board as an Executive Director from the same date. Jakob Sigurdsson will continue to serve on the Victrex Board as Chief Executive until James joins, to support an orderly transition, and then as an Executive Director. Jakob will step down from the Board at the conclusion of the Company's Annual General Meeting on 6 February 2026.
공시 • Jul 08+ 2 more updatesVictrex plc to Report Fiscal Year 2025 Results on Dec 02, 2025Victrex plc announced that they will report fiscal year 2025 results on Dec 02, 2025
공시 • Dec 06Victrex plc, Annual General Meeting, Feb 07, 2025Victrex plc, Annual General Meeting, Feb 07, 2025.
공시 • Dec 03Victrex plc Proposes Final Dividend for the Fiscal Year 2025, Payable on 21 February 2025Victrex plc at its AGM to be held on 7 February 2025, proposed final dividend at 46.14 pence per share (fiscal year 2024: 46.14 pence per share), with an Ex-dividend date: 23 January 2025, Record date: 24 January 2025 and Payment of final dividend: 21 February 2025.
공시 • Sep 18Victrex plc Announces in Partnership with Maxx Orthopedics Inc, FDA Grants IDE Approval for Freedom Total Knee System with Invibio PEEK-OPTIMA Femoral Component as Staged StudyVictrex plc announced that, in partnership with Maxx Orthopedics Inc, the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval for Freedom Total Knee System with Invibio PEEK-OPTIMA Femoral Component, as a staged study. The study, projected to be 120 patients at clinical sites in the US, will compare using the PEEK-OPTIMA Femoral Knee Component to a controlled registry of the same system using traditional metal femoral components. The US study will build on the existing clinical trial for PEEK Knee at sites in Belgium, India and Italy, which has been progressing strongly since the first implant in 2021, with no clinical intervention. A regulatory submission in India is also expected imminently, supporting the potential for a commercial PEEK Knee in the market in 2025.
공시 • Sep 06Victrex plc to Report Fiscal Year 2024 Results on Dec 03, 2024Victrex plc announced that they will report fiscal year 2024 results on Dec 03, 2024
공시 • May 15Victrex plc Announces Interim Dividend , Payable on June 28, 2024Victrex plc announced that an interim dividend of 13.42 pence per share (First half 2023: 13.42 pence) will be paid on 28 June 2024 to shareholders on the register at the close of business on 31 May 2024. This dividend will be recognised in the period in which it is approved.
공시 • Mar 15Victrex plc Appoints Urmi Prasad Richardson as Non-Executive Director, Effective from May 1, 2024Victrex plc announced that Urmi Prasad Richardson has been appointed as a non-executive director of the Board, effective from May 1, 2024. Urmi has a wealth of global experience in executive and non-executive roles over a 25 year period. She has a particular focus on science, medical and innovation based businesses. Urmi is currently President EMEA of Thermo Fisher Scientific, a world leader in serving science, with products which help accelerate life science research and improve patient health. Her executive career includes roles at The Linde Group, where she was Global Head of Healthcare, at Novartis and Foundation Medicine (a Roche company). She started her career with G.D. Searle (a Pfizer company) and has worked throughout Europe and the US. Urmi has extensive experience in strategy, business development and product commercialisation in Europe, Asia and North America. Urmi holds a number of advisory Board roles at unlisted organizations in the sectors of longevity, blockchain, and targeted therapy in oncology. Her previous non-executive roles include Linde Healthcare.
공시 • Feb 27Victrex plc to Report First Half, 2024 Results on May 13, 2024Victrex plc announced that they will report first half, 2024 results on May 13, 2024
공시 • Feb 09Victrex plc Provides Earnings Guidance for the First Half and Full Year of Fiscal Year 2024Victrex plc provided earnings guidance for the first half and full year of fiscal year 2024. First half revenue is expected to be lower than the prior year period.The Group previously communicated that progress in revenue for fiscal year 2024.
공시 • Dec 05+ 1 more updateVictrex plc, Annual General Meeting, Feb 09, 2024Victrex plc, Annual General Meeting, Feb 09, 2024.
공시 • Oct 14Victrex Announces New Product Grade Launch, Victrex Pharmaceutical Contact (PC)101 (VICTREX PC101), Developed Exclusively for the Drug Delivery Device MarketVictrex plc have launched a new product grade developed exclusively for Drug Delivery and Pharmaceutical Contact applications. VICTREX PC101™ meets the highest levels of Industry biocompatibility certification for USP Class VI and also meets industry standards such as USP 661 for use in non-implantable pharmaceutical contact applications. This material is available in granules and film and adds value to pharmaceutical production companies and drug delivery device manufacturers by providing access to assured materials for equipment or devices. This has the potential to save them cost, time and reduce risk, ultimately streamlining the commercialisation of their own products. VICTREX PC101™ is a PEEK-based material ideally suited to non-implantable Pharmaceutical contact and drug delivery applications for less than 24-hour tissue contact duration, whether they are production line equipment or primary packaging and end delivery devices. Victrex also offers unparalleled expertise, experience and support to customers, having been the first to commercialise the use of PEEK over 40 years ago. PEEK materials have properties meeting high levels of physical and chemical performance, ideal for applications requiring sterilisation, retention of dimensional stability, or chemical, electrical and temperature resistance. PEEK also meets high levels of mechanical performance, perfectly suited for high strength and miniature parts, wear, abrasion and fatigue exposure. It is also versatile for thermoplastic processing through moulding processes, milling or additive manufacturing. Victrex offer a unique perspective on this market as their medical business, Invibio, has over 20 years of proven clinical history in implantable medical PEEK devices. This insight and experience have enabled them to become a key player in the drug delivery device space over recent years. They are well placed to collaborate with OEMs, engineers and pharma manufacturing companies to support them from design, regulatory approval, manufacture and beyond.
공시 • Jul 07Victrex plc to Report Q4, 2023 Results on Dec 04, 2023Victrex plc announced that they will report Q4, 2023 results on Dec 04, 2023
공시 • May 10+ 1 more updateVictrex plc to Report Q2, 2023 Results on May 09, 2023Victrex plc announced that they will report Q2, 2023 results on May 09, 2023
공시 • Dec 06Victrex plc, Annual General Meeting, Feb 10, 2023Victrex plc, Annual General Meeting, Feb 10, 2023.